Ertugliflozin for Type 2 Diabetes

被引：2
|
作者：
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2018年 / 319卷 / 23期
关键词：
D O I：
10.1001/jama.2018.5840
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2434 / 2435
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus
    Liu, Jie
    Tarasenko, Lisa
    Pong, Annpey
    Huyck, Susan
    Wu, Larry
    Patel, Shrita
    Hickman, Anne
    Mancuso, James P.
    Gantz, Ira
    Terra, Steven G.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (08) : 1277 - 1284
  • [22] Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes
    Frias, Juan Pablo
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2019, 14 (02) : 75 - 83
  • [23] Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phaseIIIstudies
    Pratley, Richard
    Charbonnel, Bernard
    Patel, Shrita
    Hickman, Anne
    Liu, Jie
    Tarasenko, Lisa
    Pong, Annpey
    Ellison, Misoo C.
    Huyck, Susan
    Gantz, Ira
    Terra, Steven G.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (12): : 2276 - 2286
  • [24] COST EFFECTIVENESS OF EMPAGLIFLOZIN VS. ERTUGLIFLOZIN IN PATIENTS WITH TYPE-2 DIABETES
    Supner, P.
    Park, T.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S367 - S368
  • [25] The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
    Sahasrabudhe, V.
    Terra, S. G.
    Hickman, A.
    Saur, D.
    Shi, H.
    O'Gorman, M.
    Zhou, Z.
    Cutler, D. L.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (11): : 1432 - 1443
  • [26] EFFECTS OF ERTUGLIFLOZIN ON BLOOD PRESSURE AND PULSE RATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Liu, Jie
    Pong, Annpey
    Gallo, Silvina
    Darekar, Amanda
    Terra, Steven
    Lauring, Brett
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1810 - 1810
  • [27] The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus
    Sahasrabudhe, V.
    Terra, S. G.
    Fountaine, R. J.
    Hickman, A.
    Saur, D.
    Matschke, K.
    Shi, H.
    O'Gorman, M.
    Chakravarthy, M. V.
    Cutler, D. L.
    [J]. DIABETOLOGIA, 2015, 58 : S359 - S359
  • [28] Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus
    Powell, Jason
    Garland, Scott G.
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 478 - 485
  • [29] Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV
    Pratley, Richard E.
    Dagogo-Jack, Samuel
    Charbonnel, Bernard
    Cherney, David
    Cosentino, Francesco
    Mcguire, Darren K.
    Essex, Margaret N.
    Jones, Philip L. S.
    Liu, Jie
    Adamsons, Ingrid A.
    Lawrence, David
    Shih, Weichung J.
    Cannon, Christopher P.
    [J]. DIABETES, 2021, 70
  • [30] Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus
    Segar, Matthew W.
    Kolkailah, Ahmed A.
    Frederich, Robert
    Pong, Annpey
    Cannon, Christopher P.
    Cosentino, Francesco
    Dagogo-Jack, Samuel
    McGuire, Darren K.
    Pratley, Richard E.
    Liu, Chih-Chin
    Maldonado, Mario
    Liu, Jie
    Cater, Nilo B.
    Pandey, Ambarish
    Cherney, David Z., I
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (09): : 1829 - 1839
12345